Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001246914 | SCV001420306 | uncertain significance | Long QT syndrome | 2019-11-06 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with ANK2-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with serine at codon 393 of the ANK2 protein (p.Ala393Ser). The alanine residue is moderately conserved and there is a moderate physicochemical difference between alanine and serine. |
Ambry Genetics | RCV004639535 | SCV005138570 | uncertain significance | Cardiovascular phenotype | 2024-06-09 | criteria provided, single submitter | clinical testing | The p.A393S variant (also known as c.1177G>T), located in coding exon 11 of the ANK2 gene, results from a G to T substitution at nucleotide position 1177. The alanine at codon 393 is replaced by serine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |